1. Albertsen PC. Prostate cancer screening and treatment: where have we come from and where are we going? BJU Int. 2020;126(2):218–24.
2. Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018;102(2):199–214.
3. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650–5.
4. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform [−2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/mL: a multicentric European study. Eur Urol. 2013;63(6):986–94.
5. Mearini L, Ferri C, Lazzeri M, Bini V, Nunzi E, Fiorini D, et al. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Urol Int. 2014;93(2):135–45.